内容摘要 compared PIs was the BMS 045 study completed in 2006. This was a96-week comparison of ATV/r and LPV/r combined with tenofovir plus another NRTI in 358 treatment-experienced patients. Although the study examined treatment-experienced population, it does offer the clinician useful look at the comparison data. At 96 weeks, there was comparable efficacy and safety with mean biological reductions from baseline of -2.29and -2.08 log copies/ml in the ATV/r and LPV/r arms, respectively. The data from both of these studies offers reassurance that LPV/r is not the only efficacious boosted PI regimen. 4. Initial NNRTI When deciding on which NNRTI to select, one may examine the 2NNstudy, which compared not only EFV to NVP but also EFV combined with NVP. This study was completed in 2004 and enrolled 1216 HIV-infected, treatment-naive patients randomized to 1 of 4 arms: NVP 400 mg daily(QD), NVP 200 mg BID, EFV 600 mg QD, or NVP/EFV 400/800 mg QD(van Leth et al., 2003). Each arm included 3TC/d
以下为对购买帮助不大的评价